AtriCure (ATRC) Upgraded to C- at TheStreet

TheStreet upgraded shares of AtriCure (NASDAQ:ATRC) from a d+ rating to a c- rating in a research report released on Friday morning.

ATRC has been the topic of a number of other reports. BidaskClub raised shares of AtriCure from a hold rating to a buy rating in a report on Saturday. Piper Jaffray Companies reiterated a buy rating and set a $24.00 target price on shares of AtriCure in a research note on Sunday, December 10th. ValuEngine upgraded AtriCure from a sell rating to a hold rating in a research note on Wednesday, March 7th. Needham & Company LLC reiterated a buy rating and set a $23.00 target price on shares of AtriCure in a research note on Tuesday, February 27th. Finally, Canaccord Genuity lifted their target price on AtriCure from $24.00 to $26.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. AtriCure currently has an average rating of Buy and a consensus target price of $24.67.

How to Become a New Pot Stock Millionaire

AtriCure stock opened at $19.83 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.87 and a current ratio of 2.58. The stock has a market cap of $726.80, a price-to-earnings ratio of -23.89 and a beta of 0.30. AtriCure has a fifty-two week low of $14.88 and a fifty-two week high of $25.18.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Monday, February 26th. The medical device company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.13. The firm had revenue of $46.06 million for the quarter, compared to the consensus estimate of $45.85 million. AtriCure had a negative net margin of 15.39% and a negative return on equity of 16.74%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.27) EPS. sell-side analysts anticipate that AtriCure will post -0.83 earnings per share for the current fiscal year.

In related news, SVP Justin J. Noznesky sold 4,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $17.03, for a total value of $68,120.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. The disclosure for this sale can be found here. Insiders own 11.90% of the company’s stock.

A number of institutional investors have recently made changes to their positions in ATRC. BlackRock Inc. grew its holdings in AtriCure by 22.1% during the 4th quarter. BlackRock Inc. now owns 2,731,558 shares of the medical device company’s stock valued at $49,823,000 after buying an additional 494,306 shares in the last quarter. Citadel Advisors LLC grew its holdings in AtriCure by 1,193.9% during the 3rd quarter. Citadel Advisors LLC now owns 334,565 shares of the medical device company’s stock valued at $7,484,000 after buying an additional 308,708 shares in the last quarter. Cortina Asset Management LLC grew its holdings in AtriCure by 101.4% during the 3rd quarter. Cortina Asset Management LLC now owns 440,072 shares of the medical device company’s stock valued at $9,844,000 after buying an additional 221,605 shares in the last quarter. Peregrine Capital Management LLC grew its holdings in AtriCure by 22.7% during the 4th quarter. Peregrine Capital Management LLC now owns 1,134,406 shares of the medical device company’s stock valued at $20,692,000 after buying an additional 209,666 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its holdings in AtriCure by 9.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 900,296 shares of the medical device company’s stock valued at $20,140,000 after buying an additional 75,827 shares in the last quarter. Institutional investors and hedge funds own 87.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/03/20/atricure-atrc-upgraded-to-c-at-thestreet.html.

AtriCure Company Profile

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply